Conditional TRF1 knockout in the hematopoietic compartment leads to bone marrow failure and recapitulates clinical features of dyskeratosis congenita

F Beier, M Foronda, P Martinez… - Blood, The Journal of …, 2012 - ashpublications.org
Blood, The Journal of the American Society of Hematology, 2012ashpublications.org
TRF1 is part of the shelterin complex, which binds telomeres and it is essential for their
protection. Ablation of TRF1 induces sister telomere fusions and aberrant numbers of
telomeric signals associated with telomere fragility. Dyskeratosis congenita is characterized
by a mucocutaneous triad, bone marrow failure (BMF), and presence of short telomeres
because of mutations in telomerase. A subset of patients, however, show mutations in the
shelterin component TIN2, a TRF1-interacting protein, presenting a more severe phenotype …
Abstract
TRF1 is part of the shelterin complex, which binds telomeres and it is essential for their protection. Ablation of TRF1 induces sister telomere fusions and aberrant numbers of telomeric signals associated with telomere fragility. Dyskeratosis congenita is characterized by a mucocutaneous triad, bone marrow failure (BMF), and presence of short telomeres because of mutations in telomerase. A subset of patients, however, show mutations in the shelterin component TIN2, a TRF1-interacting protein, presenting a more severe phenotype and presence of very short telomeres despite normal telomerase activity. Allelic variations in TRF1 have been found associated with BMF. To address a possible role for TRF1 dysfunction in BMF, here we generated a mouse model with conditional TRF1 deletion in the hematopoietic system. Chronic TRF1 deletion results in increased DNA damage and cellular senescence, but not increased apoptosis, in BM progenitor cells, leading to severe aplasia. Importantly, increased compensatory proliferation of BM stem cells is associated with rapid telomere shortening and further increase in senescent cells in vivo, providing a mechanism for the very short telomeres of human patients with mutations in the shelterin TIN2. Together, these results represent proof of principle that mutations in TRF1 lead to the main clinical features of BMF.
ashpublications.org